Patents Examined by Isaac Shomer
  • Patent number: 11318097
    Abstract: Provided herein are liposomal vesicles comprising at least a first lipid bilayer and a second lipid bilayer, and a plurality of crosslinkages between the first lipid bilayer and the second lipid bilayer, wherein the plurality of crosslinkages comprise boronic ester or thioketal bonds. Also provided are pharmaceutical compositions comprising the liposomal vesicles described herein and a pharmaceutically acceptable excipient. Also provided are methods of making and using the liposomal vesicles. Thus, a method of treating a subject with a disease comprising administering to the subject a pharmaceutical composition comprising the liposomal vesicles is described herein. Methods of making multilamellar liposomal vesicles responsive to reactive oxygen species are also provided.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: May 3, 2022
    Assignee: Verily Life Sciences LLC
    Inventors: Zhan Wang, Stephen Morton
  • Patent number: 11311493
    Abstract: This invention relates to methods of preparing nanotherapeutic compounds and compositions comprising nanotherapeutic compounds. The nanotherapeutic compounds prepared according to the methods provided herein are useful for the treatment of disease, for example, cancer, in a subject in need thereof.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: April 26, 2022
    Assignee: MAA Laboratories, Inc.
    Inventor: Anjani Kumar Jha
  • Patent number: 11304901
    Abstract: The present invention is directed to a liposomal formulation having a lipid ingredient encapsulating fluticasone furoate, and a method for preparing the liposomal formulation. The liposome formulation comprises a lipid and a sterol. The method of preparing the liposomes comprises the steps of (1) mixing fluticasone furoate with lipid ingredients comprising a lipid and a sterol, (2) injecting the mixture into normal saline solution, and (3) ultrafiltering and concentrating the resulting solution. This preparation method can produce a liposome formulation having desirable properties and compositions, for example, the ratio of the lipid ingredient, the drug to lipid ratio, and the pH value, which is suitable for nebulization inhalation.
    Type: Grant
    Filed: August 25, 2020
    Date of Patent: April 19, 2022
    Assignee: ANOVENT PHARMACEUTICAL (U.S.), LLC
    Inventors: Cai Gu Huang, Hailong Zhang, Abid Hussain
  • Patent number: 11304902
    Abstract: The present disclosure generally relates to the field of medicine. The present invention more specifically relates to a pharmaceutical composition comprising the combination of (i) at least one biocompatible nanoparticle comprising, or consisting in, at least one natural compound which is an inhibitor of a human CYP enzyme, the longest dimension of said nanoparticle being of at least 4 nm and less than 100 nm, and (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the combination of the at least one biocompatible nanoparticle and of the at least one compound of interest potentiates the at least one compound of interest's bioavailability.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: April 19, 2022
    Assignee: CURADIGM SAS
    Inventors: Agnes Pottier, Matthieu Germain, Laurence Poul, Marion Paolini, Marie-Edith Meyre
  • Patent number: 11298375
    Abstract: The present invention provides the methods and composition useful as a contraceptive by preventing motile sperm from reaching a mature ovum, thereby blocking fertilization and preventing pregnancy. The contraceptive is comprised of halogen functionalized fullerene nanoparticles (halo fullerenes) and chemotactic stimulants that act synergistically to divert, incapacitate and ultimately rupture spermatozoa to avert fertilization. When applied vaginally prior to coitus, the suspension is activated by exposure to spermatozoa upon insemination. Notably, non-spermatozoa cells are unaffected by the pH-neutral suspension; however, closer to the same scale, microbes are susceptible to its inherent biocidal properties. Following application and coitus, the contraceptive evacuates naturally, along with seminal and vaginal fluids thereafter.
    Type: Grant
    Filed: October 12, 2021
    Date of Patent: April 12, 2022
    Inventors: Terry Earl Brady, Anthony Lee Dellinger, Melinda K. M. Goddard, Kristen Dellinger
  • Patent number: 11285111
    Abstract: A particle-producing method is provided including the processes of: discharging a liquid from discharge holes provided on a liquid-storing unit storing the liquid to make the liquid into droplets, the liquid containing a physiologically active substance and a polymer; and solidifying the droplets into a particle.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: March 29, 2022
    Assignee: RICOH COMPANY, LTD.
    Inventors: Naoki Shiraishi, Tatsuru Moritani, Tadahiko Morinaga
  • Patent number: 11285088
    Abstract: Silica particles having a d50 median particle size of at least 6 ?m, a ratio of (d90?d10)/d50 from 1.1 to 2.4, a RDA at 20 wt. % loading from 40 to 200, and a sphericity factor (S80) of at least 0.9, are disclosed, as well as methods for making these silica particles, and dentifrice compositions containing the silica particles.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: March 29, 2022
    Assignee: Evonik Operations GmbH
    Inventors: William J. Hagar, Terry W. Nassivera, Karl W. Gallis
  • Patent number: 11278023
    Abstract: Compositions for controlled release of active ingredients and methods of making same are generally provided. In some embodiments, the composition comprises an active ingredient and a delivery material. In some embodiments, the composition comprises a volatile or gaseous active ingredient useful for applications in at least one of agriculture, pest control, odor control, and food preservation. In some embodiments, the active ingredient is a cyclopropene. In some embodiments, the active ingredient is an essential oil, a terpene, or a terpenoid. In some embodiments, the delivery material is a carbon material or a silicate material.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: March 22, 2022
    Assignee: Hazel Technologies, Inc.
    Inventors: Adam Truett Preslar, Aidan R. Mouat
  • Patent number: 11273122
    Abstract: The present invention relation to an oral care composition comprising a cannabinoid and at least one pharmaceutical active component is provided in which the at least one pharmaceutical active component improves oral health beyond benefits provided by the at least one cannabinoid alone. The at least one pharmaceutical active component can be Manuka honey. The oral care composition can be used in an oral care product for whitening or bleaching teeth.
    Type: Grant
    Filed: February 11, 2020
    Date of Patent: March 15, 2022
    Inventor: Therese Mainella
  • Patent number: 11273124
    Abstract: The invention provides functionalized antifungal-loaded liposomal formulations targeting Candida, which minimize damage to healthy human cells, limit antimicrobial exposure, and reduce the development of antifungal resistance.
    Type: Grant
    Filed: March 24, 2020
    Date of Patent: March 15, 2022
    Assignee: Brown University
    Inventors: Anita Shukla, Sarah Cowles, Noel Vera-Gonzalez, Christina Bailey-Hytholt, Eli Silvert
  • Patent number: 11260007
    Abstract: In a cosmetic composition according to the present invention, a coating membrane with a multilayer lamella structure is formed on the outside of ceramide particles by using phytosphingosine, and therefore, the cosmetic composition is stably present without ceramide precipitation even in formulations with low viscosity as well as high viscosity although the particles contain a high content of ceramide, and a cosmetic composition showing an excellent skin barrier recovery effect can be provided.
    Type: Grant
    Filed: January 21, 2019
    Date of Patent: March 1, 2022
    Assignee: LG HOUSEHOLD & HEALTH CARE LTD.
    Inventors: Kyo Hoon Lee, Ei Suk Kim
  • Patent number: 11260033
    Abstract: Some embodiments pertain to nanoparticle-based compositions and their use in methods for the delivery of CBD to subjects. In some embodiments, the compositions are stable for prolonged periods of time and provide enhanced bioavailability.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: March 1, 2022
    Assignee: DISRUPTION LABS INC.
    Inventors: Brian R. Sloat, Michael A. Sandoval, Tyler B. West
  • Patent number: 11260032
    Abstract: A nano drug delivery system includes a biofilm-coated drug nanocrystal. A drug in a physical form of nanocrystal is directly used as a rigid supporting skeleton, and is filled in a biofilm. The nano drug delivery system has the advantages of high drug loading capacity, good biocompatibility, long systemic circulation time and drug sustained release.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: March 1, 2022
    Assignee: Shanghai Whittlong Pharmaceutical Institute
    Inventors: Weiyue Lu, Zhilan Chai, Xuefeng Hu, Cao Xie, Huimin Hou, Hao Wang
  • Patent number: 11260126
    Abstract: The present invention provides acoustically activated liposome compositions for use as drug delivery vehicles, and to methods for drug release and drug delivery for therapeutic applications.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: March 1, 2022
    Assignee: University of Otago
    Inventors: John Noble James Reynolds, Eng Wui Tan, Brian Ian Hyland, Guy Nicholas Louis Jameson, Maung Mo Aung Myint, Sean Marshall Mackay, Jeffery Russell Wickens
  • Patent number: 11253533
    Abstract: Injectable Ivermectin solution is safely administrable to humans and animals used the disclosed technology. A macrocyclic lactone cyclodextrin complex which is completely dissolvable or dissolved in water in a ratio of at least 5 or 10 mg of macrocyclic lactone to 1 mL of water. The macrocyclic lactone cyclodextrin complex is non-toxic, without using organic solvents, and in embodiments, formed by adding a surfactant to the macrocyclic lactone complex to water. The macrocyclic lactone cyclodextrin complex is Ivermectin or an Ivermectin derivative in some embodiments. The cyclodextrin complex is 2-hydroxypropyl-beta-cyclodextrin in some embodiments of the disclosed technology. The surfactant can be polysorbate 80 and is in a ratio of 0.01% to 25%, by weight, to said water. The water soluble complexes can be added to the water. The water-soluble complexes can have at least one of an anti-parasitic, anti-viral and anti-cancer complex.
    Type: Grant
    Filed: June 30, 2021
    Date of Patent: February 22, 2022
    Assignee: MOUNTAIN VALLEY MD INC
    Inventor: Michael Farber
  • Patent number: 11254583
    Abstract: A titanium oxide powder of the present invention has a BET specific surface area of 5 m2/g or more and 15 m2/g or less and contains polyhedral-shaped titanium oxide particles having eight or more faces, in which a mass reduction rate in a case of being heated at 800° C. for 1 hour in an air atmosphere is 0.03% by mass or more and 0.5% by mass or less.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: February 22, 2022
    Assignee: SUMITOMO OSAKA CEMENT CO., LTD.
    Inventors: Teppei Yakubo, Tsutomu Nozoe, Tetsuro Itagaki
  • Patent number: 11253482
    Abstract: The present invention relates to a biodegradable multilayer nanocapsule for the delivery of at least one biologically active agent into at least one target cell consisting of at least two layers of at least two biodegradable polymers which are laid one onto the other and whereby the biologically active agent is layered onto a layer of a biodegradable polymer and covered with a further layer of a biodegradable polymer, whereby one biologically active agent is a nucleic acid.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: February 22, 2022
    Assignees: Albert-Ludwigs-Universitaet Freiburg, Queen Mary University of London
    Inventors: Gleb Sukhorukov, Irina Nazarenko, Yana Tarakanchikova, Toni Cathomen, Tatjana Cornu, Valentina Pennucci, Jamal Alzubi
  • Patent number: 11246877
    Abstract: Prodrugs containing lipid moieties attached to drug derivatives, such as anti-cancer drug derivatives, via linkers comprising disulfide groups are described. Also described are nanoparticles coated with a lipid layer containing the prodrugs, formulations comprising the nanoparticles, and the use of the nanoparticles in methods of treating diseases, such as cancer, alone or in combination with additional drug compounds, targeting agents, and/or immunotherapy agents, such as immunosuppression inhibitors that target the CTLA-4, PD-1/PD-L1, IDO, LAG-3, CCR-7 or other pathways, or multiple immunosuppression inhibitors targeting a combination of such pathways. Optionally, the nanoparticles can comprise a photosensitizer or a derivative thereof and can be used in methods involving photodynamic therapy. Synergistic therapeutic effects result from combinations of multiple modalities provided by the disclosed nanoparticles and/or nanoparticle formulations.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: February 15, 2022
    Assignee: The University of Chicago
    Inventors: Wenbin Lin, Xiaopin Duan, Christina Chan, Wenbo Han
  • Patent number: 11241393
    Abstract: A method for treating, attenuating or inhibiting an infection and/or disease associated with a SARS virus in a subject is provided that includes administering a pharmaceutical composition to the subject. The composition includes an organosilicone carrier with one or more active substances that block and/or inhibit an ACE2 receptor in a host cell of the subject, the spike protein of a SARS virus and/or internal components of a virion of the SARS virus.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: February 8, 2022
    Inventor: Zoser B. Salama
  • Patent number: 11234932
    Abstract: Embodiments of the present invention are directed to particles having a Bryoid and a HDAC inhibitor for the treatment of latent viral disease.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: February 1, 2022
    Assignee: APHIOS CORPORATION
    Inventor: Trevor Percival Castor